Home/Kinea Bio/Michael Cho, JD

MC

Michael Cho, JD

Chief Financial Officer, Chief Strategy Officer, General Counsel

Therapeutic Areas

Neuromuscular Diseases

Kinea Bio Pipeline

Drug	Indication	Phase
DMD Gene Therapy	Duchenne Muscular Dystrophy	Pre-clinical
Dysferlinopathy Gene Therapy	Dysferlinopathy (LGMD2B/LGMDR2)	Pre-clinical
DM1 Therapy	Myotonic Dystrophy Type 1	Research

Leadership Team at Kinea Bio

Martin K. (Casey) Childers, DO, PhD

Chief Executive Officer

Jeffrey Chamberlain, PhD

Co-founder, Chief Scientific Advisor

Seung Wook Oh, PhD

Chief Operating Officer

View full Kinea Bio profile